<DOC>
	<DOCNO>NCT02765828</DOCNO>
	<brief_summary>This purpose study determine tongue strength tongue ultrasound measurement differentiate patient untreated late-onset Pompe Disease ( LOPD ) patient acquires/hereditary myopathy neuropathy . It hypothesize abnormality tongue function structure patient LOPD may useful discriminate condition others similar presentation .</brief_summary>
	<brief_title>Identification Tongue Involvement Late-Onset Pompe Disease</brief_title>
	<detailed_description />
	<mesh_term>Glycogen Storage Disease Type II</mesh_term>
	<mesh_term>Glycogen Storage Disease</mesh_term>
	<criteria>age ≥ 12 year confirm diagnosis LOPD naïve enzymereplacement therapy ( ERT ) acquired/hereditary myopathy ( e.g. , dermatomyositis , polymyositis , inclusion body myositis , limbgirdle muscular dystrophy , distal myopathy , myotonic muscular dystrophy , myopathy ) neuropathy ( e.g. , peripheral neuropathy , cranial neuropathy , autonomic neuropathy , focal neuropathy ) current use , history within past two year use , eligible decline use Lumizyme® enzyme replacement therapy ( applicable LOPD group ) history stroke , Parkinson 's disease , oculopharyngeal muscular dystrophy , head neck cancer radiation treatment head/neck , condition commonly affect lingual strength inability follow direction study participation</criteria>
	<gender>All</gender>
	<minimum_age>12 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>